gilead partner galapago glpg report posit finch
phase data adult moderate/sever rheumatoid arthriti ra prior
inadequ respons biolog agent efficaci result filgotinib broadli
similar previous report studi compet jak-inhibitor upadacitnib non-
approv baricitinib approv limit safeti data press releas
impli cleaner safeti profil believ result decept better
expect risk/benefit profil finch indic dose filgotinib
could get approv wherea risk/benefit profil upadacitnib impli like
baricitnib lower dose might get approv view finch clear
albeit earli win jak crown await greater visibl
ra autoimmun diseas caus chronic inflamm joint
progress multipl drug approv ra refer disease-
modifi anti-rheumat agent dmard methotrex gener
first-lin treatment anti-tnf agent multipl approv see
mani class approv like antagonist antagonist jak
inhibitor current treatment gener consid effect
variou third-parti market research firm like evalu pharma estim
anti-rheumat market grow due
signific patent expir among anti-tnf drug like humira see
larg dynam market signific chang next decad therapi
develop need demonstr compel risk/benefit profil ease-
oral jak inhibitor ra develop first
pan-jak inhibitor tofacitnib approv ra late
next oral jak-inhibitor baricitnib approv ra interestingli
approv lower dose fda cite convinc efficaci
benefit yet increas safeti risk higher dose
confer greater benefit safeti disclosur indic littl addit
risk higher dose report thrombosi pulmonari embol
pe opportunist infect filgotinib specif bugaboo fda
class drug
light risk/benefit finch data less clear profil
jak inhibitor includ upadacitnib compar studi select-beyond
believ filgotinib could best-in-class jak inhibitor ra two approv
dose await in-depth finch data upcom medic confer
finch studi updat number
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi stabil near term resurg
hiv busi growth addit kite axi-cel nash
off-set flat sales/non-gaap ep
opco model averag rel peer-group metric
believ risk/reward balanc
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
phase data nash pbc psc yescarta
year follow-up data phase data cle
selonsertib phase
data nash
data nash
complet list catalyst exhibit
hcv sale trough next one two year stable/up
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
look receiv fda actual
alreadi approv europ discuss
approv japan share data data submit
fda data submit everi countri around world
approv proactiv ask countri add
label warn said patient high risk thromboembol event
use caution saw studi person everi patient
thromboembol event talk death patient
still baricitinib thromboembol event
day patient histori dvt high risk dvt
proactiv ask impact uptak
product physician took transpar thank
inform rememb label look like alreadi rheumatoid arthriti
got malign infect kind realli devast side effect physician
use manag especi rheumatolog done work
 differ label scenario think someth especi
look data biggest thing think come adcom
anomali actual dvt look number dvt
studi versu competitor either one market
jak similar statist significantli differ
mean apples-to-appl studi number event anomali
zero placebo look five versu
four five versu zero anomali realli placebo group
incid well within rheumatoid arthriti patient incid
put baricitinib regular risk get dvt
similar risk baricitinib discharg
risk differ placebo activ baricitinib accord
fda think
mean disagre fda discuss benefit risk
milligram sinc
thromboembol event pulmonari embol small number patient
predisposit risk venou thromboembol
actual preval similar background occurr patient
popul happen placebo zero studi
argument opportun file data complement
origin file includ anoth placebo-control studi asia
see thromboembol event placebo also extens trial
baricitinib gone continu data similar
background report therapi occurr also data atop
dermat ye anoth patient popul least see
thromboembol event think solidifi discuss
indic baricitinib could mani atop dermat repres
recent data look promis clearli compani
jak inhibitor tri number autoimmun diseas think
also sometim pave way us way direct molecul toward
most-lik success stori optimist baricitinib gener
way would see hope construct discuss fda
regard thromboembol event baricitinib continu monitor real
world evid launch commerci well accumul data
resubmiss know last time submit januari
much data resubmit everyth seen seen
noth atop dermat studi everyth consist said
normal background rate rheumatoid arthriti patient popul
new news report
term addit data help us let start
background rate actual okay background rate rheumatoid arthriti
patient popul alreadi per patient year gener
rheumatoid arthriti patient baricitinib would incid
report say background rate similar
specif background rate develop program per patient
year also say sinc submit real world evid
atop dermat data accumul background rate
still within gener rate rheumatoid arthriti patient hope
clarifi background rate similar see without use baricitinib
patient popul addit data think discuss fda
clinic trial program submit januari sinc
typic fda look approv drug say safe effect
balanc real world evid look
tri protect patient patient actual real
world baricitinib import actual see real world
use baricitinib realli play
patient physician use clinic practic way someon
normal would control environ believ give even
confid background rate match rheumatoid arthriti clinic trial
well real world evid consist look
atop dermat think thing confirm look patient
popul patient actual thromboembol event one
patient high risk thromboembol event
atop dermat trial see much younger patient popul part
reason probabl see phase trial seen far
anticip see mani differ move forward
phase trial
select inhibitor upadacitinib disclos five trial
rheumatoid arthriti studi drug first-lin therapi patient nave
treatment way patient fail prior tnf inhibitor
look upa without methotrex demonstr superior
humira patient worth data everi one
contact upa perform top class certainli direct although
head-to-head studi direct better see baricitinib
tofacitinib think shown safeti perspect rate venou
thromboembol becom point discuss class realli
differ placebo random control trial worsen
time demonstr type dose respons
look safeti safeti play essenti exactli
expect lot concern period time base situat
evolv baricitinib around rate dvt pe program
alway said head end program show peopl data
said along way play-by-play account rare event use
mislead whole dataset put public domain
last studi peopl see rate dvt pe
observ rate exactli upadacitinib methotrex
numer lower humira think highlight challeng rare
event individu studi humira studi obvious head-
to-head long-term extens phase rate similar
evid increas risk event signal mind
evid program look overal safeti ph rate today
larg line one would expect immuno-
modulatori agent treat ra patient look adalimumab head-to-head
studi look seriou overal upadacitinib compar
favor humira would say whole packag efficaci
safeti packag realli met exceed expect
turn attent safeti base total data remain
confid overal safeti profil upadacitinib respect gener
rate specif event occurr dvt pe say
dvt pe second look overal profil believ
consist mechan action also consist
immunomodulatori agent use treat ra patient major advers
experi mild moder result discontinu therapi
frequent event shown third panel includ
detail relev press releas subsequ present ultim
manuscript becom avail overal feel data show
favor benefit risk profil upa support well-character
well-conduct clinic trial program manag safeti strong efficaci
across patient popul turn attent rate dvt pe
program collect refer vte obvious
consider attent paid occurr event jak clinic trial
recent unblind five core clinic studi
posit show event rate pre-upadacitinib treat patient compar
patient across program control period long-term extens
phase data shown chart see see
control period shown first row rate upa-tr patient
similar observ patient receiv placebo methotrex fact
overal upa rate event per patient year rate
observ placebo methotrex lower rate least numer
observ adalimumab also import note
evid dose respons upa milligram upa milligram
event look lower half chart show long-
term extens period show rate placebo methotrex
agent continu extens period ra clinic trial
see upa rate describ similar rate
control period also numer lower adalimumab import note
evid dose respons base data see
evid increas risk occurr vte upa-tr patient
across program
think compound far demonstr time time well-
control placebo-control well-design trial remark
perform efficaci addit safeti profil continu demonstr
data accumul best-in-class profil guy
know surpris high select think
need would imagin phase trial would expect
actual phase trial filgotinib ra also ibd later
continu demonstr superb efficaci along best-in-class safeti
combin actual excel outstand risk benefit profil
turn question safeti cours heighten
issu peopl mind ad com also recent present data
on-going open label studi darwin eular would week
approxim two year actual point open label data
want steal thunder quit comfort data
come today share think dvt thromboembol event
rate still low level around event per patient
actual quit pleas far
great ambit filgotinib profil base data gener far
phase studi rheumatoid arthriti crohn diseas
excit filgotinib safeti toler profil promis best-in-class
believ due high select data
patient year exposur to-dat consist impress favor
safeti advers event profil expect present long-term data two
year treatment darwin open-label studi rheumatoid arthriti
patient upcom acr meet year
need two larg data set two phase clinic trial bolster
safeti program look posit difficult treat
group patient rheumatoid arthriti biolog inadequ respond
may respond last respons multipl biolog agent mani
expos two three even biolog agent difficult trace
group patient rheumatoid arthriti term question matthew
read easier treat patient think augur well
address term phase stellar trial nash interim
analysi interim analysi endpoint one interim analys
endpoint approv subpart week biopsi studi
actual continu five year dmc cours look
safeti data regularli obviou safeti signal risk/benefit
chang would know far recommend
chang either phase studi term conduct term filgotinib
male safeti studi enrol studi someth
address believ margin adequ beyond minor histolog
abnorm see pre-clin model evalu data
come
compani report oppenheim co
indicationdrugtimingmilestonehivvesatolimod phase studi hiv phase studi prephematology/oncologyyescarta axicabtagen enrol phase follow data enrol phase indol nhl phase combo enrol phase studi line dlbcl enrol phase phase adult phase pediatr phase studi enrol phase studi anti-bcma car-t registr studi base phase enrol phase studi mage solid ind tcr target solid endpoint phase combo studi r/r cllotherremdesivir phase studi ebola survivorsnash pbc psc stellar phase data stellar phase data fxr data nash pbc psccombin interim data phase studi selonsertib and/or and/or patient advanc fibrosi due phase studi ankylos phase finch studi phase finch studi enrol phase select studi divers studi enrol crohn phase studi cutan lupu phase studi sjogren syndrom inc
epclusa- vosevi- hcv descovy- vemlidy- bic/ftc/taf- hiv total axi-cel- selonsirtib- total total product perform na
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax inc
stock price compani mention report
